Emerald BioStructures

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB have extended a collaboration aimed at identifying multiple targets in the drug discovery process, Emerald announced on Thursday.

The firms achieved a second milestone in their drug discovery pact, which utilizes Emerald's X-ray crystallography platform.

Movers & Shakers

Premium

John Hunt, John McCall, John Mulligan, Lynn Silver

The agreement with NEC, which has purchased an equity stake in the company, is part of its plan to expand beyond its traditional focus on biomarker discovery and diagnostics development to become a "health information company" that can "provide actionable medical information to patients, physicians, and researchers," said an official.

The firms are building on a collaboration from last year, under which they unraveled the first X-ray structure of a DNA aptamer bound to its protein target.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.